Curran Simpson serves as the Executive Vice President and Chief Operating Officer at REGENXBIO Inc., a leading biotechnology company focused on the development and commercialization of gene therapies. In his role, Simpson is responsible for overseeing the company's operational strategy and execution, ensuring that REGENXBIO's innovative therapies progress from development to market efficiently and effectively. His leadership is pivotal in navigating the complex landscape of gene therapy, from manufacturing to regulatory compliance, and ultimately, to patient access. Before joining REGENXBIO, Simpson amassed a wealth of experience in the biopharmaceutical industry. He held various leadership positions at notable companies such as MedImmune and Amgen, where he honed his skills in operations, strategic planning, and business development. At MedImmune, he played a key role in the successful launch and commercialization of several biologics, demonstrating his ability to drive growth and innovation. His strategic foresight and operational expertise have been instrumental in positioning REGENXBIO as a frontrunner in the gene therapy field. Simpson's achievements extend beyond his corporate roles; he is also recognized for his contributions to the broader biopharma community. He has been a speaker at numerous industry conferences, sharing insights on the future of gene therapy and the operational challenges and opportunities it presents. Under his guidance, REGENXBIO has made significant strides in advancing its pipeline of gene therapy candidates, bringing hope to patients with severe genetic diseases. His dedication to improving patient outcomes and his strategic vision continue to drive REGENXBIO's mission to revolutionize the treatment of genetic disorders.